Avid Bioservices Inc (CDMO)

[freethemice]

There is another positive. If the second-line NSCLC MOS data is as strong as it looks to be then
the size of the phase III trial won't have to be that large. Maybe only 2-3 times the size of the phase II trial,
especially as there will likely only be one bavi dose arm. That means it will take less money and so
Peregrine can retain more of its leverage.